If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.
AbbVie seeks EU approval to expand MAVIRET use for acute Hepatitis C treatment
Healthcaremea
If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.
